Taken together our data suggest that PI3K and FGFR or CDK4/6 inhibitor combinations or single inhibitor CT/RT combinations may provide possible therapeutic opportunities for therapy of resistant MBs and should be investigated further. The gene discussed is CDK4; the disease is Mobius syndrome.